Rates of reported nausea were similar at 52 weeks, and lower than they had been at 30 weeks (7.0% for the once-weekly group and 7.7% among those who switched). Injection-site pruritus was reported by 0.8% of the once-weekly group at 52 weeks, compared with 4.6% of the switchers. Again, no severe hypoglycemia occurred and mild hypoglycemia occurred among only the patients also taking sulfonylureas, he reported.